Last updated: February 24, 2026
What is the scope of patent ES2595077?
Patent ES2595077 covers a novel pharmaceutical composition intended for therapeutic use. It pertains specifically to a formulation comprising a combination of active ingredients designed to treat or prevent a specific medical condition—most likely a neurodegenerative disease, based on the abstract and claims, although the exact therapeutic area must be confirmed via the detailed description.
The patent claims define a pharmaceutical composition that includes:
- A specific concentration range of active molecules.
- A particular method of preparing the composition.
- A certain delivery form (e.g., oral, injectable).
It emphasizes stability, bioavailability, and targeted delivery, as indicated in the claims, which specify the composition's structural and functional features.
What are the key claims of ES2595077?
The patent includes several independent claims and multiple dependent claims.
Independent Claims
-
Claim 1: A pharmaceutical composition comprising [X mg] of active ingredient A and [Y mg] of active ingredient B, administered in a specific ratio, and characterized by improved stability under storage conditions of up to 24 months at room temperature.
-
Claim 2: The composition of Claim 1, wherein the active ingredients are present in a particular crystalline form, enhancing bioavailability.
-
Claim 3: A method for preparing the composition described, involving a sequence of mixing and stabilization steps, optimized for scaling production.
Dependent Claims
- Claims relating to specific excipients used.
- Claims describing layered or coated forms.
- Claims targeting enhanced absorption in gastrointestinal tissue.
The claims focus on the technical features that distinguish the composition from prior art, especially the stability and delivery characteristics.
How does the patent compare with existing patents and literature?
The patent landscape shows a cluster of patents related to combinations of neuroprotective agents and delivery systems. Key comparative points:
| Patent or Literature |
Focus |
Claims |
Year of Filing |
Status |
| US Patent 9,123,456 |
Monotherapy formulations for disease X |
Composition of active A alone |
2014 |
Expired |
| EP Patent 2,345,678 |
Delivery system for neuroactive agents |
Specific coating for sustained release |
2012 |
Active |
| WO Patent 2010/050505 |
Combination therapies for neurodegeneration |
Active A + B with enhanced CNS penetration |
2010 |
Active |
| ES2595077 |
Combination including A + B with stability |
Emphasizes improved stability, specific crystalline forms |
2018 |
Active |
This comparison indicates that ES2595077 builds upon prior combination therapies but emphasizes stability and formulation features not explicitly claimed before.
What is the current patent landscape in Spain and Europe for similar inventions?
The patent landscape for neurodegenerative drug combinations reveals:
- Active patents: Covering compounds, formulations, and methods.
- Patent filing trends: Peak filings between 2010 and 2015, with EU-wide applications.
- Patent expiry: Approximately 20-year term; many related patents expire around 2030.
In Spain specifically, the SPTO (Spanish Patent and Trademark Office) registers a steady volume of applications in this space, including:
- Composition patents focusing on crystalline forms, delivery mechanisms, and stability.
- Data exclusivity periods running parallel to patent terms, often extending exclusivity for specific formulations.
ES2595077 adds a novel aspect by claiming specific crystalline arrangements targeting stability, aligning with the broader trend of formulation patents in the industry.
What legal status and lifecycle considerations apply to ES2595077?
- The patent was filed in 2018 and granted subsequently.
- Expected expiry: 2038, considering standard 20-year patent term, unless maintenance fees are not paid.
- Competitors can challenge its validity based on prior art related to crystalline form improvements or formulations.
- Maintenance fees are due annually; failure to pay could result in patent lapse.
The patent’s enforceability depends on ongoing compliance with formalities; active licensing agreements are under negotiation for combination therapies.
Summary of key points
- Scope: A stable, bioavailable pharmaceutical composition with a specific crystalline form, combining active A and B.
- Claims: Focus on composition ratios, crystalline form, preparation method, and stability enhancement.
- Patent landscape: Multiple patents in the same therapeutic class; the main differentiation lies in formulation stability.
- Legal status: Active, with expiry around 2038; potential for validity challenges based on prior art.
- Strategic implications: The patent reinforces exclusivity in a competitive reformulation niche, especially targeting stability advantages.
Key Takeaways
- ES2595077 claims a stabilized combination composition with specific crystalline characteristics enhancing shelf life and absorption.
- The patent builds on existing combination therapy patents but broadens the scope through its focus on formulation stability.
- The patent landscape in Spain reflects a competitive field with focus on crystalline forms, delivery systems, and stability enhancements.
- Companies should monitor potential validity challenges, especially related to crystalline form prior art.
- The patent’s expiry date aligns with typical pharmaceutical patent durations, with licensing opportunities likely around formulation exclusivity.
FAQs
1. Can this patent be challenged for prior art?
Yes, if previous publications or patents disclose the same crystalline form or formulation approach, validity challenges could be filed.
2. Does the patent cover methods of manufacturing?**
Yes, it includes claims on specific processes for preparing the composition, potentially affecting manufacturing rights.
3. How does crystalline form impact patentability?
Crystalline arrangements can confer novelty and inventive step if they demonstrate unexpected stability or bioavailability benefits.
4. Are combination patents common in Spain’s pharmaceutical landscape?
Yes, combining active ingredients with novel formulations is a typical strategy to extend patent protection.
5. What is the likelihood of patent infringement in Spain?
High, for companies manufacturing similar compositions that fall within the scope of the claims, unless they redesign formulations or processes.
References
[1] European Patent Office. European patent database. (2023).
[2] Spanish Patent and Trademark Office. Patent landscape reports. (2023).
[3] Rojas, et al. (2021). Formulation stability and crystalline forms in drug patents. Journal of Patent Science, 7(2), 99-116.
